Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 9, 2024, reports on the announcement of statistically significant overall survival (OS) results from a planned interim analysis of the DREAMM-7 Phase III clinical trial. The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting. The trial evaluates Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus daratumumab in combination with bortezomib plus dexamethasone (DVd) as a second-line or later treatment for relapsed or refractory multiple myeloma.
Key Financial and Clinical Metrics
The filing focuses on clinical trial outcomes rather than corporate financial metrics such as revenue, profit, or cash flow. No financial data is provided in this document.
Clinical Trial Results (DREAMM-7):
- Overall Survival (OS): The BVd arm demonstrated a 42% reduction in the risk of death compared to the DVd arm (Hazard Ratio 0.58; p=0.00023).
- Projected Median OS: 84 months for BVd versus 51 months for DVd (median not reached in either arm).
- 3-Year OS Rate: 74% for BVd versus 60% for DVd.
- Minimal Residual Disease (MRD) Negativity: 25.1% for BVd versus 10.4% for DVd (p<0.00001).
- Overall Response Rate (ORR): 83.1% for BVd versus 71.3% for DVd.
- Duration of Response (DOR): Median 40.8 months for BVd versus 17.8 months for DVd.
- Safety: Grade 3+ adverse events included thrombocytopenia (56% BVd vs 35% DVd). Eye-related side effects led to a 10% discontinuation rate.
Material Changes and Regulatory Status
The filing highlights a material advancement in the treatment of multiple myeloma, establishing Blenrep combinations as a potential new standard of care due to the significant OS benefit. Regulatory filings for Blenrep combinations based on DREAMM-7 and DREAMM-8 data have been accepted in seven major markets: the US, European Union, Japan, China, United Kingdom, Canada, and Switzerland. Several of these filings have received priority review or Breakthrough Therapy Designation.
Outlook, Risks, and Management Commentary
Management Commentary: GSK leadership described the data as a "paradigm shift" that could redefine treatment for relapsed or refractory multiple myeloma, emphasizing the potential to significantly extend patient lives.
Outlook: The company anticipates that Blenrep combinations may become the standard of care. The DREAMM clinical development program continues, with the DREAMM-10 Phase III study in newly diagnosed transplant-ineligible patients expected to initiate by the end of 2024.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2023 Form 20-F and Q3 2024 results. Specific clinical risks include known side effects of belantamab mafodotin, particularly eye-related issues, though these were generally manageable.
Key Facts for Investor Verification
- Verify the regulatory approval timelines for Blenrep combinations in the US, EU, and other major markets following the accepted filings.
- Monitor the final data readout of the DREAMM-7 trial to confirm the projected median overall survival of 84 months.
- Assess the commercial impact of Blenrep becoming a standard of care in the second-line or later treatment setting for multiple myeloma.
- Review the initiation status and design of the upcoming DREAMM-10 trial for newly diagnosed patients.
- Confirm the safety profile and real-world management of eye-related adverse events in broader patient populations.